Print
Email
Print Edition StoriesThursday, September 17, 2009
MLSC-backed Wadsworth gets FDA approval for wound-closure system
By Mass High Tech staff
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Marc Songini: Researchers focus on macular degeneration
MHT's Marc Songini: RI plans launch of cord blood center
Wadsworth Medical Technologies, an investment portfolio firm of the Massachusetts Life Sciences Center, has been granted FDA approval for its noninvasive, needleless wound-closure system, called DermaLOC. As a result, and with the FDA’s “minimal risk” rating, the company can market the system for human use.
The Westborough medical device firm was one of the first companies to receive funding, a $400,000 Accelerator loan in April, from the Massachusetts Life Sciences Center, or MLSC, a quasi-public agency tasked with overseeing the state’s $1 billion Life Sciences Initiative. The Accelerator program provides $3.4 million to life sciences firms in the state. Each company is eligible for as much as half a million dollars to support research and development, manufacturing and sales.
Wadsworth’s DermaLOC system is made to close skin wounds using tension.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
